Biocon Limited has announced that its Malaysia insulin manufacturing facility has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line, as per the exchange filings.
The approval covers the manufacturing of Semglee® (insulin glargine) and marks an important regulatory milestone for the company's insulin business in Europe.
The European Medicines Agency has approved a new drug product fill finish unit at Biocon's insulin manufacturing facility in Malaysia.
The approved line will be used for the production of Semglee (insulin glargine), expanding the company's manufacturing capabilities for regulated international markets.
Biocon said commercial supplies from the newly approved production line are expected to commence in Q2FY27.
The approval is expected to support the company's insulin supply chain for the European market while enhancing manufacturing flexibility and capacity.
The regulatory clearance reinforces Biocon's manufacturing standards and strengthens its ability to supply insulin products to regulated markets.
The company believes the additional fill finish capacity will support its long-term strategy of expanding access to insulin therapies across international markets.
Read More: RBI Fixes SGB 2019-20 Series II Premature Redemption Price at ₹14,199 for July 16, 2026!
As of 16 July 2026, at 12:07 PM, Biocon share price was trading at ₹442.55 per share, reflecting a surge of 1.83% from the previous trading session.
The EMA approval for Biocon's new fill finish line in Malaysia marks a key regulatory achievement for its insulin business. With supplies to Europe scheduled to begin in Q2FY27, the approval is expected to strengthen the company's global manufacturing and supply capabilities.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 16, 2026, 12:39 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
